The ongoing Iran War is causing a ripple effect across the global pharmaceutical supply chain, with potential long-term consequences for healthcare systems worldwide. While the immediate concern is not a complete depletion of medications, the war's impact on shipping routes and airspace is causing significant disruptions and raising costs, which could exacerbate existing shortages and make it harder to access essential medicines.
The American Society of Health-System Pharmacists (ASHP) has identified several critical medicines currently in short supply or facing supply pressure. These include ADHD medications like Adderall and Vyvanse, painkillers such as oxycodone and hydrocodone, cancer treatments like carboplatin and methotrexate, and basic hospital injectables like lidocaine, fentanyl, and ketamine. The list also includes essential IV fluids and antibiotics, highlighting the diverse range of medications affected.
One of the most concerning aspects of this crisis is the potential increase in the cost of producing and transporting these medications. Gerren McHam, vice president of external affairs at the API Innovation Center, warns that the instability caused by the war could lead to longer lead times and higher transportation costs for key drug ingredients, which are essential for the synthesis of active pharmaceutical ingredients.
However, Michael Ganio, senior director of pharmacy practice and quality for ASHP, offers a more optimistic perspective. He suggests that the pharmaceutical industry has weathered similar drug shortages in the past and is familiar with mitigation strategies. Ganio also points out that some drugs closely tied to Israel are niche medicines, which may limit their broader impact on patients.
The underlying issue, according to experts, is the global supply chain itself. The Middle East, while not a significant producer of medicines, plays a crucial role in air cargo and shipping routes, which are essential for the distribution of many drugs and raw materials. Disruptions in these routes could have far-reaching consequences for the availability and accessibility of medications worldwide.
In conclusion, the Iran War is creating a complex and multifaceted challenge for the pharmaceutical industry, with potential implications for global healthcare. As the conflict continues, it is essential to closely monitor the situation and implement strategies to ensure the continued availability of essential medicines, especially in regions that rely heavily on these supplies.
